Singapore's ASLAN gets second U.S. FDA orphan designation for ASLAN001

FDA sign

Singapore-based ASLAN Pharmaceuticals said its pan-HER inhibitor varlitinib (ASLAN001) has received a U.S. FDA orphan designation for a second indication in gastric cancer, the third most common cancer in Asia.

The biotech won its first orphan designation for ASLAN001 in August of last year for a treatment for cholangiocarcinoma, a rare and aggressive form of bile duct cancer. The approval came after the candidate announced plans to work with Taiwan's ACT Genomics to explore a better-than-expected therapeutic response in which one patient showed 87% tumor shrinkage over a prolonged period of time.

ASLAN, which received Phase II trial nods for the candidate in Singapore and Taiwan last year, has also signed a pact with South Korea's Hyundai Pharmaceutical for the first co-development agreement on ASLAN001.


Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

Also last year, ASLAN notched up positive Phase I results with gastric cancer candidate ASLAN002, licensed from Bristol-Myers Squibb ($BMY). The drug is heading to Phase II.

The company also has preclinical candidate ASLAN003, a DHODH inhibitor, licensed from Almirall, currently in Phase I trials for rheumatoid arthritis, and ASLAN004, a fully human monoclonal antibody against interleukin-13 receptor α1 that has been shown to block binding and signal transduction of both IL4 and IL13, which was licensed from CSL.

In 2015, ASLAN secured $22 million in Series B financing led by Shanghai-based Cenova Ventures, which joined Morningside Group and XinChen Ventures with BioVeda Capital and Sagamore Bioventures, to fund ongoing clinical development of ASLAN's portfolio.

Sources said the company is eyeing raising more capital and eventually listing in either Asia or the U.S.

Related Articles:
Singapore's ASLAN Pharmaceuticals expands work with Spain's Almirall on ASLAN003
Singapore's ASLAN marks a first for ASLAN001 with Hyundai Pharm
ASLAN gets U.S. FDA orphan designation on ASLAN001


Suggested Articles

Saturday, AstraZeneca revealed more of the data that convinced the FDA to green-light Calquence in previously untreated chronic lymphocytic leukemia.

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.